How has been the historical performance of Titan Biotech?

Answer:The historical performance of Titan Biotech shows a fluctuating trend in key financial metrics over the years. Breakdown: Titan Biotech's net sales have shown variability, with a peak of 164.07 Cr in Mar'24, followed by a decline to 156.45 Cr in Mar'25. Total operating income mirrored this trend, reaching 164.07 Cr in Mar'24 before decreasing to 156.45 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 129.79 Cr in Mar'24 to 131.02 Cr in Mar'25. Operating profit (PBDIT) also saw a decline from 34.28 Cr in Mar'24 to 25.43 Cr in Mar'25, reflecting a decrease in operating profit margin from 20.89% to 16.25%. Profit before tax decreased from 31.53 Cr in Mar'24 to 24.37 Cr in Mar'25, leading to a profit after tax of 18.27 Cr in Mar'25, down from 23.66 Cr in Mar'24. The consolidated net profit followed suit, decreasing from 24.85 Cr in Mar'24 to 21.53 Cr in Mar'25. On the balance sheet, total assets rose from 157.03 Cr in Mar'24 to 174.71 Cr in Mar'25, while total liabilities also increased from 157.03 Cr to 174.71 Cr. The company maintained a stable equity capital of 8.26 Cr over the years. Cash flow from operating activities remained relatively stable, with a slight decrease from 21.00 Cr in Mar'24 to 20.00 Cr in Mar'25, while net cash inflow improved from a negative 2.00 Cr in Mar'24 to a positive 2.00 Cr in Mar'25. Overall, Titan Biotech's financial performance reflects challenges in profitability despite growth in total assets.